{"id":"W4214935792","doi":"10.1016/j.esmoop.2022.100410","title":"Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Janssen Research and Development; EMD Serono; Genentech; Ipsen; PharmaMar; Astellas Pharma; National Institute for Health and Care Research; Seagen; G1 Therapeutics; AstraZeneca España; Daiichi-Sankyo; ViewRay; BeiGene; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; TG Therapeutics; Amgen; Boehringer Ingelheim; Elekta; Taiho Pharmaceutical; Mirati Therapeutics; Varian Medical Systems; Takeda Pharmaceutical Company; AbbVie; Sanofi; Celgene; Novartis; Manchester Biomedical Research Centre; Merck; GlaxoSmithKline; Daiichi Sankyo Europe; Servier; Bayer; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Incyte; Pfizer; Roche; Astellas Pharma US","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Hazard ratio; Clinical endpoint; Internal medicine; Post-hoc analysis; Stage (stratigraphy); Oncology; Lung cancer; Cancer; Clinical trial; Confidence interval; Pembrolizumab; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004351264,0.001103688,0.00195423,0.0002849748,0.0003458349,0.0009337545,0.0007788066,0.0006859053,0.001997049],"category_scores_gemma":[0.00310881,0.0002989806,0.003583837,0.0005741064,0.0007086027,0.000793328,0.0006536557,0.001879573,0.0002848319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001140152,"about_ca_system_score_gemma":0.001298269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000942475,"about_ca_topic_score_gemma":0.002285525,"domain_scores_codex":[0.9980134,0.001220372,0.0001154789,0.0002427191,0.0001911082,0.000216969],"domain_scores_gemma":[0.9975709,0.0007430948,0.0006342303,0.0003595746,0.0001458628,0.0005462735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.917106,0.004602208,0.04337622,0.0006476403,0.008242036,0.0001925495,0.0001291772,0.002014928,0.004055284,0.0002341746,0.002016975,0.01738293],"study_design_scores_gemma":[0.4159749,0.2628363,0.2858993,0.0002207405,0.01642414,0.0006214855,0.0003196502,0.005000165,0.004818109,0.0013272,0.006430195,0.000127732],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954637,0.001454851,0.0002237888,0.0001689577,0.00003219832,0.0004892755,0.001389387,0.00001336772,0.0007645433],"genre_scores_gemma":[0.9935005,0.0006327138,0.0003978075,0.0002665622,0.00009340213,0.0009188166,0.003535368,0.00001207154,0.0006426497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004351264,"threshold_uncertainty_score":0.02301192,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02197590166635086,"score_gpt":0.3131541527190675,"score_spread":0.2911782510527167,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}